[1] ZHENG YX, MA SJ, LU MH.Diagnostic estimation of noninvasive tests for hepatic fibrosis in chronic hepatitis B patients without a gold standard[J]. Hepatitis Monthly, 2016, 16(2):1.
[2] PENG Y, ZHAO TJ, FAN WH.Combination effects of entecavir and compound biejiaruangan tablet on serum hepatic fibrosis markers of chronic hepatitis B by meta analysis[J]. Medicinal Plant, 2015, 6(11/12):42.
[3] SHI JP, FAN JG, Wu R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol, 2008, 23(9):1419. doi: 10.1111/j.1440-1746.2008.05531.x
[4] 董文婿, 吕春燕, 彭捷, 等.肝纤四项检测在慢性乙肝病毒感染者中的临床价值分析[J].医学理论与实践, 2019, 32(2):260.
[5] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华循环杂志, 2016, 31(10):937.
[6] PETERSMANN A, MVLLER-WIELAND D, MVLLER UA, et al.Definition, classification and diagnosis of diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2019, 127(S01):S1.
[7] 梁扩寰, 李绍白.肝脏病学[M]. 2版.北京:人民卫生出版社, 2003:101.
[8] 陈欢, 李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者肝功能及血脂水平分析[J].医学信息, 2019, 32(12):67.
[9] 孙涛, 杜凤梅, 戴立娟.恩替卡韦治疗对慢性乙型肝炎患者血糖和血脂的影响[J].肝脏, 2019, 24(06):680.
[10] 王鹏, 张志侨, 吕国涛, 等.慢性乙型肝炎患者不同肝纤维化分期时血脂、血糖和尿酸代谢异常发生率及其临床意义[J].中华传染病杂志, 2017, 35(7):398.
[11] 谢昭宁.乙型肝炎患者血清纤维化指标与血脂水平检测的临床意义[J].华夏医学, 2014, 27(3):22.
[12] 沈月爽, 李萌, 吴国友.慢性乙型肝炎患者血清血脂和载脂蛋白水平的研究[J].中国卫生检验杂志, 2015, 25(16):2758.